Publications.
Engstrom A, Hannibal TD, Egli J, Gauthier B, Krarup ML, Gallo D, Jensen AE, Van Cruchten S, Bulera S, Cornet M, Hammer SE, Henry D, Jacobsen B, Kendrick J, Madsen LS, Mhedhbi S, Oag S, Pedersen HD, Teti M, Singh P. Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics. Regul Toxicol Pharmacol. 2025 Sep:161:105855.
Engstrom A, Hannibal TD, Egli J, Gauthier B, Krarup ML, Gallo D, Jensen AE, Van Cruchten S, Bulera S, Cornet M, Hammer SE, Henry D, Jacobsen B, Kendrick J, Madsen LS, Mhedhbi S, Oag S, Pedersen HD, Teti M, Singh P. Corrigendum to “Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics” [Regul Toxicol Pharmacol. 2025;161:105855]. Regul Toxicol Pharmacol. 2025 Nov;162:105908.
Eckstein Y, Kessler B, Hinrichs A, Novak I, von Thaden A, Lorenzen T, Rathkolb B, Scholz A, Blutke A, Koopmans SJ, Hrabĕ de Angelis M, Christoffersen BØ, Wolf E, Renner S. Protocol for in vivo assessment of glucose control and insulin secretion and sensitivity in the pig. STAR Protocols. April 2025;6.
Funding acknowledgement
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101165643. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe and Breakthrough T1D and VeriSIM Life.
Funding acknowledgement
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101165643. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe and Breakthrough T1D and VeriSIM Life.